Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency PURPOSE: We conducted a retrospective ...
NEW YORK (Reuters) - Genzyme Corp held its second investor meeting in two months to argue that its most promising experimental drug will capture five times the sales that Sanofi-Aventis has assumed in ...
Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In ...
Combining Fludara (fludarabine), Cytoxan (cyclophosphamide), and Rituxan (rituximab) was safer and produced a higher response than pairing Campath (alemtuzumab) with Fludara and Cytoxan in patients ...
Genzyme Corp., resisting a hostile takeover by Sanofi-Aventis SA, said its blood-cancer drug Campath worked against multiple sclerosis, an added use that helps justify a higher price than Sanofi’s $69 ...
Sixty-nine consecutive patients (median age 54 years) were prospectively enrolled in a single-institution protocol for allogeneic transplantation with adjusted non-myeloablative ...
Genzyme is stepping up its presence in the currently hot oncology world by extending relationships with Bayer Healthcare for three drugs compounds. The deal between the two biotech companies will ...
One of the big sticking points in the potential Sanofi-Aventis/Genzyme deal has been sales estimates for Campath, the company's leukemia drug that it's developing for multiple sclerosis. Genzyme has ...
Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on lymphocytes and monocytes. Pulsed administration causes prolonged T-cell depletion and has been shown to be effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results